60
Participants
Start Date
July 22, 2020
Primary Completion Date
January 31, 2021
Study Completion Date
January 31, 2021
Experimental Group
Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
Placebo Group
Continued standard of care therapy together with matching placebo
University of Texas Medical Center, Dallas
University of Texas Southwestern Medical Center
OTHER